IN2013MU02015A - - Google Patents

Download PDF

Info

Publication number
IN2013MU02015A
IN2013MU02015A IN2015MU2013A IN2013MU02015A IN 2013MU02015 A IN2013MU02015 A IN 2013MU02015A IN 2015MU2013 A IN2015MU2013 A IN 2015MU2013A IN 2013MU02015 A IN2013MU02015 A IN 2013MU02015A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
composition comprises
acceptable excipients
fixed dose
Prior art date
Application number
Other languages
English (en)
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to PCT/GB2014/051772 priority Critical patent/WO2014199131A1/en
Priority to IN2015MU2013 priority patent/IN2013MU02015A/en
Publication of IN2013MU02015A publication Critical patent/IN2013MU02015A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
IN2015MU2013 2013-06-13 2014-06-10 IN2013MU02015A (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/GB2014/051772 WO2014199131A1 (en) 2013-06-13 2014-06-10 Fixed Dose Pharmaceutical Composition
IN2015MU2013 IN2013MU02015A (es) 2013-06-13 2014-06-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2015MU2013 IN2013MU02015A (es) 2013-06-13 2014-06-10

Publications (1)

Publication Number Publication Date
IN2013MU02015A true IN2013MU02015A (es) 2015-07-10

Family

ID=51022895

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2015MU2013 IN2013MU02015A (es) 2013-06-13 2014-06-10

Country Status (2)

Country Link
IN (1) IN2013MU02015A (es)
WO (1) WO2014199131A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008105058A1 (ja) * 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur

Also Published As

Publication number Publication date
WO2014199131A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
TR201908596T4 (tr) Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları.
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019501076A1 (en) Pharmaceutical formulations
MX2016008429A (es) Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria.
EP3731832A4 (en) CANNABINOID DOSAGE FORM
IN2013MU01696A (es)
IN2013MU00711A (es)
PH12016501841A1 (en) Immunosuppressant formulation
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
IN2013MU01985A (es)
EA201991265A1 (ru) Лекарственные формы с отсроченным высвобождением, содержащие диметилфумарат
MX2018005350A (es) Formulacion de combinacion de dosis fija, eflornitina y sulindaco.
PH12018502524A1 (en) Physiologically balanced injectable formulations of fosnetupitant
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
IN2013MU02015A (es)
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
IN2013MU03370A (es)
MX2016010104A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria.
IN2013MU03310A (es)
IN2014MU00077A (es)
UA92173U (ru) Фармацевтическая композиция для применения в ветеринарии